Multimodal Approach for Identification and Validation of Hepatocellular Carcinoma Targets for Radiotheranostics
Authors:
- Philip HomanPHPhilip Homan
- Joon-Yong ChungJoon-Yong Chung
- Woonghee LeeWLWoonghee Lee
- Divya NambiarDNDivya Nambiar
- Julia Sheehan-KlenkJSJulia Sheehan-Klenk
- Hima MakalaHMHima Makala
- Stanley FaynSFStanley Fayn
- Orit JacobsonOJOrit Jacobson
- Arthur Paden KingAKArthur Paden King
- Kyungeun KimKKKyungeun Kim
- Jeong Won KimJKJeong Won Kim
- Sung Ryol LeeSLSung Ryol Lee
Preprint
Abstract
Identifying tumor selective targets is critical for the development of precision diagnostic and therapeutic agents in oncology. Despite advances in precision oncology elsewhere, there are no FDA-approved hepatocellular carcinoma (HCC)-selective treatments. HCC is the most common type of liver cancer and accounts for significant morbidity and mortality worldwide. Here, we sought to integrate bulk (371 cases) and single cell RNA sequencing (scRNAseq, n =2 datasets, 34 cases, 102,956 cells) of patient samples to enrich for molecules that are overexpressed in HCC, which could serve as HCC-selective targets. To guide definitions of tumor and normal cell clusters with higher fidelity, we also imported a normal liver scRNAseq dataset. Using this integrated approach, we identified several HCC-selective plasma membrane molecules. To validate these targets, we performed immunohistochemical staining of HCC and normal tissue microarrays and confirmed HCC-selective staining of identified targets. Next, we verified the presence of these targets in several commercially available HCC cell lines by flow cytometry and western blot. Finally, we designed, engineered, and tested novel antibody-based positron emission tomography (immunoPET) agents to these targets in various murine models of liver cancer. Our findings confirm that we can leverage this multimodal approach to identify and validate of HCC-selective targets, which can be used to develop tumor-selective diagnostic and therapeutic radiopharmaceuticals, or radiotheranostics, and other precision oncology agents. One Sentence Summary: A multimodal pipeline defines and validates tumor-selective surface targets for radiotheranostic use in hepatocellular carcinoma.Keywords
Funding Information
- NIH Intramural Research Program (ZIA BC 011800)
- NIH Intramural Research Program (ZIC BC 011891)
- Federal funds from the NCI, National Institutes of Health, Department of Health and Human Services (75N91019D00024)
This publication has 74 references indexed in Scilit:
- Interpretive consistency of a qualitative 68Ga-PSMA PET framework for treatment response assessment in hepatocellular carcinoma: a head-to-head comparison with cross-sectional imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2025
- Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistanceCancer and Metastasis Reviews, 2024
- CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancerCancer Immunology, Immunotherapy, 2023
- PET imaging with FAPI-ligands for non-cirrhotic hepatocellular carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Ga‐PSMA‐11 PET Using Cyclotron‐Produced 68GaHepatology Communications, 2021
- Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic CancerJAMA Oncology, 2021
- Engineered Anti‐GPC3 Immunotoxin, HN3‐ABD‐T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum RetentionHepatology, 2019
- Glypican‐3‐Specific Antibody Drug Conjugates Targeting Hepatocellular CarcinomaHepatology, 2019
- Overexpression of MUC13, a Poor Prognostic Predictor, Promotes Cell Growth by Activating Wnt Signaling in Hepatocellular CarcinomaThe American Journal of Pathology, 2018
- Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivoJournal of Cancer Research and Clinical Oncology, 2017